164. The method of claim 152, wherein the obtaining step comprises obtaining a peptide of 8, 9, 10 or 11 amino acids in length.

165. The method of claim 152, wherein the obtaining step comprises obtaining a peptide of more than 11 amino acids in length, with a *proviso* that the peptide does not comprise an entire native antigen.--

D! cont

REMARKS

With this amendment, Applicants request entry of new claims 67-165 in the patent application. These claims replace the previously filed claims 16-66. Applicants thank the Examiner for the interview with Applicants' attorneys, Ellen Weber and Timothy J. Lithgow, on July 21, 1999 in which this case was discussed. The newly added claims are being submitted as discussed in the interview.

The new claims are fully supported by the present specification and in related application 08/344,824 which is incorporated by reference in the first paragraph on page 1 of the present application. The present application will be further amended as necessary to physically incorporate any essential material currently incorporated by reference that is required to support allowable claims of the present application.

Claims 67 and 85 recite a method of making an immunogenic peptide comprising an HLA B7 supermotif that binds to an HLA molecule and induces a cytotoxic T cell response; and testing a first and at least a second complex of the supermotif-bearing peptide fragment, and a first and at least a second HLA molecule for the ability to be recognized by HLA-restricted cytotoxic T cells. These claims add no new matter. Support for this amendment can be found, e.g., in the specification on page 2, lines 25-28, page 3, lines 8-9 and page 4 lines 22-25.

Claims 70, 81, 104, 114, 136, 138, 151, 158, and 160 recite determining binding affinity of a peptide for, or contacting a complex with, an HLA-B0701, HLA-B1401, HLA-B3501, HLA-B3503, HLA-B5101, HLA-B5301, HLA-B5401 or HLA-Cw6 molecule. These claims add no new matter. Support for this amendment can be found, e.g., in related

application U.S.S.N. 08/344,824, incorporated by reference, on page 33, Motif Types E and F of Table 6.

Claims 71, 80, 105, 115, and 152 recite a binding affinity of an IC_{50} of less than about 500 nM. These claims add no new matter. Support for this amendment can be found, e.g., in related application U.S.S.N. 08/344,824, incorporated by reference, on page 49, lines 27-29.

Claims 106, 134, and 153 recite an IC_{50} of less than about 125 nM. These claims add no new matter. Support for this amendment can be found, e.g., in related application U.S.S.N. 08/344,824, incorporated by reference, on page 57, Table 14.

Claims 107, 135, and 154 recite an IC_{50} of less than about 50 nM. These claims add no new matter. Support for this amendment can be found, e.g., in related application U.S.S.N. 08/344,824, incorporated by reference, on page 57, Table 14.

Claims 78, 79, 82, 83, 111, and 112, recite a testing step, or a contacting step, that occurs *in vitro* or *in vivo*. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 11, line 34 through p. 12, line 1.

Claims 88, 89, 102, 119, 120, 133, 139, 141, 142, 147, 156, 157, and 165 recite a peptide fragment, or a longer peptide, that is not an entire native antigen. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 3, line 28 through page 4, line 2.

Claims 67, 68, 80, 84, 139, 146, 152, and 164 recite an epitope of about 8-11 amino acids in length, or a peptide fragment that has 8, 9, 10, or 11 residues. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 3, lines 19-21, and on page 3, lines 5-7.

Claims 102, 147, and 165 recite a peptide or peptide fragment that is more than 11 amino acids, or residues, in length. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 12, line 32 through page 13, line 4 and page 13, lines 26-27.

Claims 90 and 121 recite a cancer associated antigen. Claims 95 and 126 recite a pathogenic antigen. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 4, lines 29-30.

Claims 91 and 122 recite HER2/neu. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 24, lines 20-21.

Claims 92 and 123 recite p53. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 24, line 20.

Claims 93 and 124 recite a melanoma antigen. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 5, line 1.

Claims 94 and 125 recite a melanoma antigen. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 24, line 19.

Claims 96 and 127 recite an HPV antigen. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 24, line 9.

Claims 97 and 128 recite an HIV antigen. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 24, line 10.

Claims 98 and 129 recite an HBV antigen. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 24, line 8.

Claims 99 and 130 recite an HCV antigen. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 24, line 9.

Claims 100 and 131 recite a malaria antigen. These amendments add no new matter. Support for these amendments can be found, e.g., in the specification on page 24, line 10.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200 or Timothy J. Lithgow at 619-860-2514.

Respectfully submitted,

Ellen Lauver Weber
Reg. No. 32,762

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
JML
SF 1018933 v1